Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 85.89% is 84% above its 5-year average of 46.64%, near the high end of its 5-year range (-4444.12%–124.42%).
0.29% above its 12-month average of 85.64%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 85.02%.
GROSS MARGIN
85.89%
GROSS MARGIN AVG TTM
85.64%
GROSS MARGIN AVG 3Y
89.51%
GROSS MARGIN AVG 5Y
46.64%
GROSS MARGIN AVG 10Y
27.39%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.29%
CURRENT VS 3Y AVG
-4.05%
CURRENT VS 5Y AVG
+84.17%
CURRENT VS 10Y AVG
+213.56%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+107.56%
vs the sector median at left
Verrica Pharmaceuticals Inc.
Market Cap
$73.57M
Gross Margin
85.89%
TTM Avg
85.64%
3Y Avg
89.51%
5Y Avg
46.64%
Market Cap
$72.83M
Gross Margin
60.78%
TTM Avg
57.02%
3Y Avg
54.79%
5Y Avg
56.72%
Market Cap
$75.06M
Gross Margin
77.06%
TTM Avg
74.09%
3Y Avg
74.09%
5Y Avg
72.46%
Market Cap
$71.22M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
Market Cap
$76.24M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$76.54M
Gross Margin
66.34%
TTM Avg
59.91%
3Y Avg
56.70%
5Y Avg
58.64%
Market Cap
$76.56M
Gross Margin
41.76%
TTM Avg
36.53%
3Y Avg
27.69%
5Y Avg
15.34%
Market Cap
$77.72M
Gross Margin
-102.47%
TTM Avg
-54.48%
3Y Avg
-12.40%
5Y Avg
10.21%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | $73.57M | 85.89% | 85.64% | 89.51% | 46.64% |
| Hyperfine, Inc. (HYPR)vs › | $73.81M | 51.41% | 47.75% | 37.98% | -14.72% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | 60.78% | 57.02% | 54.79% | 56.72% |
| Pulmonx Corporation (LUNG)vs › | $75.06M | 77.06% | 74.09% | 74.09% | 72.46% |
| Gain Therapeutics, Inc. (GANX)vs › | $71.22M | 0.00% | 0.00% | 50.00% | 66.67% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $76.24M | 100.00% | 100.00% | 100.00% | 100.00% |
| SkinHealth Systems Inc. (SKIN)vs › | $76.54M | 66.34% | 59.91% | 56.70% | 58.64% |
| Outset Medical, Inc. (OM)vs › | $76.56M | 41.76% | 36.53% | 27.69% | 15.34% |
| Sera Prognostics, Inc. (SERA)vs › | $77.72M | -102.47% | -54.48% | -12.40% | 10.21% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
85.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 85.02% |
| 2026-03-31 | 82.30% |
| 2025-12-31 | 72.49% |
| 2025-09-30 | 92.27% |
| 2025-06-30 | 96.11% |
| 2025-03-31 | 87.70% |
| 2024-12-31 | -81.69% |
| 2024-09-30 | 124.42% |
| 2024-06-30 | 89.53% |
| 2024-03-31 | 70.26% |
| 2023-12-31 | -934.56% |
| 2023-09-30 | 95.03% |
| 2023-06-30 | 25.27% |
| 2023-03-31 | -83.78% |
| 2022-12-31 | -4444.12% |
| 2022-09-30 | 98.00% |
| 2022-06-30 | -2.34% |
| 2022-03-31 | 35.50% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
